"Our long-term aim is also to help the company get into a position where it can attract the consistent funding it will need to successfully complete a Phase III clinical study and beyond. If the company is going to move into a sustainable position to attract a broader range of investors that, in turn, will give it a runway to complete its clinical trials, it needs to put these allegations to rest once and for all.... -- Neil Woodford, a month ago
Then yesterday, after previously agreeing to NWBO's plans to hire Mr. Price, he said this:
Woodford Investment Management replied that they view the level of due diligence as adequate and the investment [Northwest Biotherapeutics] remains in the portfolio. -- January 7, 2016
Yes, but IN DECEMBER Woodford also stated he intended to help NWBO make that destination a successful one in his blog dedicated entirely to Northwest Bio...
Our conviction in the technology and early clinical data, supported by globally leading oncology clinicians, is the principal factor in our investment. Our long-term aim is also to help the company get into a position where it can attract the consistent funding it will need to successfully complete a Phase III clinical study and beyond.
.
Whatever the issue is between Woodford and Linda, it's not centered around the outcome of the P3 trial.